Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

10,937 total articles

AT&T: Cheap, Cash-Generative, and Resetting — a Practical Long Trade

AT&T: Cheap, Cash-Generative, and Resetting — a Practical Long Trade

AT&T is trading at single-digit multiples with a hefty dividend and improving technicals. Strong free cash flow ($13.3B trailing), low P/E (8.4x) and an EV/EBITDA of 6.5x leave room for re-rating if revenue and margin stabilization continue. This trade idea lays out a concrete entry, stop and target with timeframes and the key risks that could dera…

After the Beat: Why I'm Adding to NVDA and How I'm Positioning the Trade

After the Beat: Why I'm Adding to NVDA and How I'm Positioning the Trade

Nvidia reported results that keep its AI leadership intact and secured a sizable AWS GPU commitment. I’m doubling my exposure with a clearly defined entry at $220.16, a stop at $200.00 and a target of $264.00 over the next 180 trading days. The setup mixes strong fundamentals, near-term catalysts and manageable technical risk — but valuation and ex…

Buy the Launch: Speculative Long on SpaceX as Debt Funds an AI Pivot

Buy the Launch: Speculative Long on SpaceX as Debt Funds an AI Pivot

SpaceX is deploying capital raised via debt to scale Starlink and build AI-optimized edge and data-center infrastructure. Public market access is limited, but secondary liquidity and structured products exist. This trade is a high-conviction, risk-managed long: enter at $250.00, stop at $200.00, target $350.00 over a 180 trading day horizon. The th…

BioCryst (BCRX): A Two-Front Play on HAE — Trade It as a Risk-Reward Swing to Clinical and Commercial Upside

BioCryst (BCRX): A Two-Front Play on HAE — Trade It as a Risk-Reward Swing to Clinical and Commercial Upside

BioCryst combines a profitable, growing oral HAE franchise (ORLADEYO) with a late-stage monoclonal antibody (navenibart) that could capture patients who prefer infrequent injections. The balance sheet and licensing proceeds materially de-risk near-term funding. With free cash flow of ~$373M and 2026 ORLADEYO guidance intact, the stock at $9.72 offe…

Pinterest: Buy the Overstated Fear — A Mid-Term Long Trade

Pinterest: Buy the Overstated Fear — A Mid-Term Long Trade

Pinterest is trading like ad revenue has already collapsed and user engagement will never recover. Recent ARPU gains, robust free cash flow of $1.28B, and a manageable balance sheet argue for a tactical long. This trade targets a rebound toward $30 over the next 45 trading days with a disciplined $20 stop.

Nvidia Q2: Beat But Not Bulletproof - A Buy-on-Weakness Trade

Nvidia Q2: Beat But Not Bulletproof - A Buy-on-Weakness Trade

Nvidia reported another beat but the stock is down on profit-taking and mixed forward signals. Fundamentals remain strong (market cap ~$5.5T, EPS $7.99, FCF $127B, ROE 84%), but the price already prices in a lot of growth (P/E ~28.8, P/FCF ~43). This trade buys the post-earnings weakness with a defined stop and a mid-term horizon to capture normali…

Covered-Call Play on Oracle: Income Now, Upside Later

Covered-Call Play on Oracle: Income Now, Upside Later

Oracle is a market-cap heavyweight ($441B) with healthy profitability, a 1.3% cash dividend and clear exposure to AI/cloud infrastructure. Use a disciplined buy-write: buy at $153.00, sell an out-of-the-money call, target $164.00 in 45 trading days and protect with a $142.00 stop. The plan aims for roughly 7% gross return from option premium + divi…

Carnival: Cheap Enough to Buy for a 6-Month Recovery

Carnival: Cheap Enough to Buy for a 6-Month Recovery

Carnival (CCL) is trading near $25 with a market cap of roughly $34.2B and an EV/EBITDA of 7.8. Strong recent operating recovery, record customer deposits and continued debt reduction argue for upside; geopolitical and fuel-cost risks argue for a tight stop. I outline a long trade with an entry at $25.00, stop at $22.50 and a $31.00 target over a 1…

Comcast Trades at Book - A Spinoff Could Close the Discount

Comcast Trades at Book - A Spinoff Could Close the Discount

Comcast is trading essentially at book value with a 5% dividend yield and strong free cash flow. A committed separation of NBCUniversal or a similar corporate action would likely re-rate the stock above current levels. This trade idea lays out a long position with clear entry, targets and stop, rooted in valuation, cash flow and catalysts tied to c…

Buying the AI-Cooling Optionality: Modine as a Mid-Term Speculative Long

Buying the AI-Cooling Optionality: Modine as a Mid-Term Speculative Long

Modine has real exposure to the fast-growing data center cooling market and a freshly public narrative: a massive hyperscale deal plus a planned spinoff of lower-margin business. The shares have pulled back into the $180s after a run; this trade targets a re-rating into the low $200s over the next 11-45 trading days while keeping a strict stop to l…

Buy the AGI Buildout: Why Heavy CapEx Makes Alphabet a Tactical Long

Buy the AGI Buildout: Why Heavy CapEx Makes Alphabet a Tactical Long

Alphabet is well positioned to lead in AGI because it owns critical assets — massive datacenters, custom silicon, DeepMind/Gemini IP and an advertising engine to monetize breakthroughs. Heavy, targeted CapEx is a deliberate strategy to secure compute advantage; this trade buys a pullback while accepting short-term earnings pressure for a multi-quar…